Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › ribavirin

ribavirin

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of ribavirin

242 trials tracked of ribavirin: 117 in phase 3 or 4 and 24 with published results. The most-cited published study has 305 citations.

242Trials tracked
117Phase 3 & 4
0Recruiting
24With published results
Phase distribution
Phase 4 32 Phase 3 85 Phase 2 90 Phase 1 7 Other / NA 28
  1. Phase 3 A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection Completed · 305 cited
  2. Phase 4 Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients Completed · 295 cited
  3. Phase 3 Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease Completed · 278 cited
  4. Phase 3 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection Completed · 230 cited
  5. Phase 3 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy Completed · 201 cited
  6. Phase 4 Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1. Completed · 182 cited
Show 44 more trials
  1. Phase 3 Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir Completed · 151 cited
  2. Phase 3 Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults Completed · 114 cited
  3. Phase 3 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection Completed · 113 cited
  4. Phase 4 Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC). Completed · 80 cited
  5. Phase 3 Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study Completed · 74 cited
  6. Phase 3 Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077) Completed · 54 cited
  7. Phase 3 A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1) Completed · 53 cited
  8. Phase 4 A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin Completed · 42 cited
  9. Phase 4 Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection Completed · 33 cited
  10. Phase 4 A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3 Completed · 16 cited
  11. Phase 3 Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection Completed · 15 cited
  12. Phase 4 Study of Oral Treatments for Hepatitis C Completed · 12 cited
  13. Phase 3 A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects Completed · 12 cited
  14. Phase 3 The Individualized Management With Pegylated-interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Offering Viral Eradication: A Study of Pegylated-interferon Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C (CHC) Non-genotype 2/3 (IMPROVE) Completed · 10 cited
  15. Phase 3 Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection Completed · 5 cited
  16. Phase 3 IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1 Completed · 3 cited
  17. Phase 3 ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis Completed · 2 cited
  18. Phase 4 A Study of PEGASYS (Peginterferon Alfa-2a) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3 Completed · 1 cited
  19. Phase 4 A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC). Completed
  20. Phase 4 A Study of Induction Dosing With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C (CHC) Genotype 1 Infection Completed
  21. Phase 4 A Study of Sustained Virological Response in Relation to IL28-b Expression in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 on Combination Treatment With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) Completed
  22. Phase 4 A Study of Peginterferon Alfa-2a (Pegasys) When Administered in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Completed
  23. Phase 4 Efficacy and Safety of Peg-Interferon Alpha-2a Plus Ribavirin in Genotype 1 Chronic Hepatitis C Participants Co-Infected With Human Immunodeficiency Virus Completed
  24. Phase 4 Individualized Triple-therapy Using Boceprevir in HIV-positive Patients With Hepatitis C Completed
  25. Phase 4 SMV + SOF With/Without RBV for IFN-II Patients With CHC Completed
  26. Phase 4 Evaluation of Unipeg® for Response and Ongoing Safety in Pakistani Population Completed
  27. Phase 4 A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) Completed
  28. Phase 4 Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics Completed
  29. Phase 4 Pegylated Interferon (PEG-IFN) Alfa-2b and Low Dose Ribavirin for the Treatment of Chronic Hepatitis C Patients With Genotype 1 High Viral Load and Low Body Weight (Study P05172)(COMPLETED) Completed
  30. Phase 4 A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C Completed
  31. Phase 4 A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Enrolled in a Methadone Maintenance Treatment Program. Completed
  32. Phase 4 Intermittent Use of Aerosolized Ribavirin for Treatment of RSV Completed
  33. Phase 4 A Study of Ribavirin in Combination With PEGASYS (Peginterferon Alfa-2a (40KD))in Patients With Chronic Hepatitis C Completed
  34. Phase 4 Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144)(COMPLETED) Completed
  35. Phase 4 A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Genotype 1 Chronic Hepatitis C Completed
  36. Phase 4 A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) Completed
  37. Phase 4 Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3 Completed
  38. Phase 4 A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection Completed
  39. Phase 4 A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance. Completed
  40. Phase 4 The Role Of Nitazoxanide, Interferon Alfa And Ribavirin In Treatment Of Hepatitis C Infected Type 2 Diabetic Patients Completed
  41. Phase 4 The SIM-SOF Trial for Hepatitis C Completed
  42. Phase 4 REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy Completed
  43. Phase 3 Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection Completed
  44. Phase 3 Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755) Completed

Showing the 50 most-cited and recently-updated of 242 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Randomized trial shows ribavirin increases mutational load and specific transition signatures in HCV
Infectious Disease
Randomized trial shows ribavirin increases mutational load and specific transition signatures in HCV Ribavirin linked to increased hepatitis C virus mutations in trial
This secondary analysis of a randomized trial in HCV-infected participants found ribavirin exposure significantly increased total mutational…
Ribavirin treatment linked to increased hepatitis C virus mutations in a trial, though real-world impact on cure rates remains unclear.
medRxiv Apr 19, 2026
Machine learning models predict SVR in comorbid HCV patients treated with sofosbuvir, daclatasvir, and ribavirin in Pakistan
Primary Care & Family Medicine Cohort
Machine learning models predict SVR in comorbid HCV patients treated with sofosbuvir, daclatasvir, and ribavirin in Pakistan Can a computer predict your hepatitis C cure?
This retrospective cohort study evaluated machine learning prediction models in 221 comorbid HCV patients in Pakistan.
A new computer tool can spot which hepatitis C patients are likely to fail treatment before they even start taking pills.
Frontiers Apr 13, 2026